These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18829568)

  • 41. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
    Friel AM; Zhang L; Curley MD; Therrien VA; Sergent PA; Belden SE; Borger DR; Mohapatra G; Zukerberg LR; Foster R; Rueda BR
    Reprod Biol Endocrinol; 2010 Dec; 8():147. PubMed ID: 21122138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133+ DAOY medulloblastoma cells.
    Annabi B; Doumit J; Plouffe K; Laflamme C; Lord-Dufour S; Béliveau R
    Mol Carcinog; 2010 Jul; 49(7):710-7. PubMed ID: 20564348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
    Ress AL; Stiegelbauer V; Schwarzenbacher D; Deutsch A; Perakis S; Ling H; Ivan C; Calin GA; Rinner B; Gerger A; Pichler M
    Oncotarget; 2014 Sep; 5(18):8492-502. PubMed ID: 25261368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting CD133 antigen in cancer.
    Ferrandina G; Petrillo M; Bonanno G; Scambia G
    Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
    Zhang C; Zhou C; Wu XJ; Yang M; Yang ZH; Xiong HZ; Zhou CP; Lu YX; Li Y; Li XN
    Carcinogenesis; 2014 Dec; 35(12):2771-7. PubMed ID: 25269803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.
    Dong TT; Zhou HM; Wang LL; Feng B; Lv B; Zheng MH
    Ann Surg Oncol; 2011 Jun; 18(6):1797-804. PubMed ID: 21267784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
    Nakai E; Park K; Yawata T; Chihara T; Kumazawa A; Nakabayashi H; Shimizu K
    Cancer Invest; 2009 Nov; 27(9):901-8. PubMed ID: 19832037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD133 gene overexpression is frequently observed in early colorectal carcinoma.
    Hibi K; Sakata M; Sakuraba K; Shirahata A; Goto T; Mizukami H; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
    Hepatogastroenterology; 2009; 56(93):995-7. PubMed ID: 19760928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD133+CD44+ population efficiently enriches colon cancer initiating cells.
    Haraguchi N; Ohkuma M; Sakashita H; Matsuzaki S; Tanaka F; Mimori K; Kamohara Y; Inoue H; Mori M
    Ann Surg Oncol; 2008 Oct; 15(10):2927-33. PubMed ID: 18663533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
    Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
    Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein.
    Osmond TL; Broadley KW; McConnell MJ
    Int J Mol Med; 2010 Jun; 25(6):883-8. PubMed ID: 20428792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Demethylation of the CD133 gene is frequently detected in early gastric carcinoma.
    Hibi K; Sakata M; Kitamura YH; Sakuraba K; Shirahata A; Goto T; Mizukami H; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
    Anticancer Res; 2010 Apr; 30(4):1201-3. PubMed ID: 20530428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
    Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells.
    Yao J; Zhang T; Ren J; Yu M; Wu G
    Oncol Rep; 2009 Oct; 22(4):781-7. PubMed ID: 19724856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
    Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
    Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
    Deng G; Chen A; Hong J; Chae HS; Kim YS
    Cancer Res; 1999 May; 59(9):2029-33. PubMed ID: 10232580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.
    Peickert S; Waurig J; Dittfeld C; Dietrich A; Garbe Y; Kabus L; Baumann M; Grade M; Ried T; Kunz-Schughart LA
    Lab Invest; 2012 Nov; 92(11):1607-22. PubMed ID: 22964855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
    Wang LJ; Bai Y; Bao ZS; Chen Y; Yan ZH; Zhang W; Zhang QG
    Chin Med J (Engl); 2013; 126(11):2062-6. PubMed ID: 23769558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.